Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (NCT00644228)
A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients With Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant
🩺 Plain-English Summary (8th-Grade Level)
This randomized phase III trial studies lenalidomide, dexamethasone, and bortezomib to see how well it works compared to dexamethasone and lenalidomide alone in treating patients with previously untreated multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer. It is not yet known whether lenalidomide and dexamethasone is more effective with or without bortezomib in treating multiple myeloma.
Who can join: Review the eligibility criteria below.
Location: Providence Alaska Medical Center — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (498 Sites)
Showing the first 25 of 498 sites.
- Providence Alaska Medical Center — Anchorage, Alaska
- Mayo Clinic in Arizona — Scottsdale, Arizona
- University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- PCR Oncology — Arroyo Grande, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Mills-Peninsula Medical Center — Burlingame, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente-Fresno — Fresno, California
- Saint Jude Medical Center — Fullerton, California
- Marin General Hospital — Greenbrae, California
- Fremont - Rideout Cancer Center — Marysville, California
- Providence Holy Cross Medical Center — Mission Hills, California
- Palo Alto Medical Foundation-Camino Division — Mountain View, California
- Sutter Cancer Research Consortium — Novato, California
- Kaiser Permanente-Oakland — Oakland, California
- Saint Joseph Hospital - Orange — Orange, California
- Desert Regional Medical Center — Palm Springs, California
- Palo Alto Medical Foundation Health Care — Palo Alto, California
- Valley Medical Oncology Consultants — Pleasanton, California
- Eisenhower Medical Center — Rancho Mirage, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in DS Stage I Multiple Myeloma
Explore by condition: All DS Stage I Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.